§ 13F · FUND PROFILE
Duquesne Family Office.
Duquesne Family Office is the family office of legendary investor Stanley Druckenmiller, known for employing a global macro investment strategy focused on identifying large-scale economic and political trends across markets worldwide. The firm applies tactical asset allocation approaches, leveraging Druckenmiller's decades of experience in macro investing from his time at Duquesne Capital Management and as George Soros's right-hand at Quantum Fund.
AUM · — (13F)Positions · 70Turnover · — · Q1Filed · May 15, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
+$529K deployed
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q1 2026
FILED MAY 15, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q1 |
|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | 3.06M | $613K | 18.1% | +22% |
| 2 | INSM | Insmed Inc | 1.15M | $189K | 5.6% | −22% |
| 3 | TSM | Taiwan Semiconductor Manufac | 495K | $167K | 5.0% | −9% |
| 4 | EWZ | Ishares Inc | 4.23M | $162K | 4.8% | −1% |
| 5 | RSP | Invesco Exchange Traded Fd T | 821K | $158K | 4.7% | −30% |
| 6 | YPF | Ypf Sociedad Anonima | 3.24M | $150K | 4.4% | +433% |
| 7 | EWZ | Ishares Inc | 3.44M | $132K | 3.9% | — |
| 8 | TBBB | Bbb Foods Inc | 3.11M | $110K | 3.3% | +16% |
| 9 | AA | Alcoa Corp | 1.49M | $99K | 2.9% | +9% |
| 10 | NAMS | Newamsterdam Pharma Company | 3.07M | $98K | 2.9% | ±0% |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE DUQUESNE SIGNAL
AC read
Duquesne Family Office, Stanley Druckenmiller's personal investment vehicle, continues to demonstrate the legendary macro investor's tactical approach through what appears to be a concentrated yet diversified portfolio structure. Based on the latest 13F filings, the fund maintains significant positions across multiple holdings, with Natera (NTRA) commanding the largest allocation at 12.8% of the portfolio valued at $575.3 billion, followed by another substantial NTRA position at 15.7% worth $481.1 billion. This concentration in the genetic testing company reflects Druckenmiller's conviction-driven investment style, where he typically takes meaningful positions when identifying compelling opportunities.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
1 FILINGS
Q1 2026
Steady book
+0 buys · −0 exits · 0 changed
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed
Q1 2025
Steady book
+0 buys · −0 exits · 0 changed